Fidelity Management & Research Co has recently announced that it has increased stake in Allogene Therapeutics Inc (NASDAQ:ALLO) by 0.91%. After grabbing 25.14 million shares, the institutional investor is now in possession of 0.23 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 15.00% having worth around $70.91 million. Moreover, The Vanguard Group, Inc. increased its share by 3.09 million to have a control over 10.45 million shares. And BlackRock Fund Advisors raised its holdings to 0.51 million shares by acquiring 7.21 million shares or 4.30% of the stake.
Allogene Therapeutics Inc (ALLO) concluded trading on 12/14/23 at a closing price of $2.71, with 4.84 million shares of worth about $13.11 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -45.47% during that period and on Thursday the price saw a gain of about 5.45%. Currently the company’s common shares owned by public are about 144.44M shares, out of which, 105.96M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 25 times over the past 12 months. They bought 6,486,902 shares in 17 of the transactions. In 8 selling transactions, insiders dumped 111,800 shares.
SPDR S&P Biotech ETF, Fidelity Select Port. – Health Ca, and Vanguard Total Stock Market ETF are the top 3 mutual funds which are holding stakes in Allogene Therapeutics Inc SPDR S&P Biotech ETF is currently holding 6.8 million shares of worth totaling $19.19 million. The company recently came buying 40660.0 shares which brought its stake up to 4.06% of the company’s outstanding shares. Vanguard Total Stock Market ETF, after buying 3.88 million shares, have now control over 2.31% of the stake in the company. It holds 0.0 shares of worth $10.93 million.
However, the stock later moved at a day high price of 2.7900, or with a gain of 5.45%. Stock saw a price change of 7.54% in past 5 days and over the past one month there was a price change of 2.26%. Year-to-date (YTD), ALLO shares are showing a performance of -56.92% which decreased to -66.17% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.23 but also hit the highest price of $8.44 during that period. The average intraday trading volume for Allogene Therapeutics Inc shares is 1.96 million. The stock is currently trading 4.07% above its 20-day simple moving average (SMA20), while that difference is down -3.03% for SMA50 and it goes to -38.68% lower than SMA200.
Fidelity Management & Research Co acquired 25.14 million shares of Allogene Therapeutics Inc having value of about $70.91 million. Data submitted at the U.S SEC by Fidelity Management & Research Co revealed that the firm now holds 0.23 million shares in the company valued at close to $612394.96, or have control over 0.91% stake in the company. Allogene Therapeutics Inc (NASDAQ: ALLO) currently have 144.44M outstanding shares and institutions hold larger chunk of about 65.86% of that. Holding of mutual funds in the company is about 42.03% while other institutional holders and individual stake holders have control over 46.47% and 24.75% of the stake respectively.
The stock has a current market capitalization of $456.04M and its 3Y-monthly beta is at 0.70. It has posted earnings per share of -$2.24 in the same period. It has Quick Ratio of 12.58 while making debt-to-equity ratio of 0.17. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALLO, volatility over the week remained 9.27% while standing at 10.10% over the month.
Analysts are in expectations that Allogene Therapeutics Inc (ALLO) stock would likely to be making an EPS of -$0.46 in the current quarter, while forecast for next quarter EPS is -$0.46 and it is -$1.83 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.62 which is -$0.34 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.66 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 13.60% while it is estimated to increase by 10.48% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on December 08, 2023 offering a Buy rating for the stock and assigned a target price of $7 to it.
